Chugai Pharmaceutical Co., Ltd. Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab," Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online
New! 【Move to another page】Quote
https://ift.tt/2KPA7zz
May 10, 2018
